Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 7/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.36 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318226 | 1.00 | LMNA (0.43) | LMNAGAAALDH1A1KDM4ECYP19A1 | |
| SCHEMBL318041 | 0.90 | LMNA (0.43) | LMNAGAAALDH1A1KDM4ECYP19A1 | |
| SCHEMBL10109092 | 0.90 | LMNA (0.43) | LMNAGAAALDH1A1KDM4ECYP19A1 | |
| SCHEMBL318173 | 0.80 | LMNA (0.47) | LMNAGAAALDH1A1KDM4ECYP19A1 | |
| SCHEMBL318058 | 0.80 | LMNA (0.47) | LMNAGAAALDH1A1KDM4ECYP19A1 | |
| SCHEMBL10108843 | 0.80 | LMNA (0.47) | LMNAGAAALDH1A1KDM4ECYP19A1 | |
| SCHEMBL10108810 | 0.80 | LMNA (0.47) | LMNAGAAALDH1A1KDM4ECYP19A1 | |
| SCHEMBL6556593 | 0.75 | SIGMAR1 (0.50) | LMNAGAAALDH1A1KDM4ECYP19A1 | |
| SCHEMBL6556380 | 0.75 | SIGMAR1 (0.50) | LMNAGAAALDH1A1KDM4ECYP19A1 | |
| SCHEMBL6556375 | 0.75 | SIGMAR1 (0.50) | LMNAGAAALDH1A1KDM4ECYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ESR2, ERLIN1, ESRRG | LMNA 2755/4885GAA 2018/4885ALDH1A1 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.